STOK News and Press, Stoke Therapeutics Inc. From 11/04/25

2025-11-04 17:16:03 ET More on Stoke Therapeutics Stoke Therapeutics: Vulnerable To Profit Taking Stoke Therapeutics names Ian F. Smith as CEO Seeking Alpha’s Quant Rating on Stoke Therapeutics Historical earnings data for Stoke Therapeutics Fi...

– Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 – – As of September 30, 2025, the Company had $328.6 milli...

2025-11-04 14:38:13 ET Thesis Read the full article on Seeking Alpha For further details see: Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

Advanced Energy Industries Inc. (AEIS) is expected to report $1.16 for Q3 2025 Neuropace Inc. (NPCE) is expected to report $-0.2 for Q3 2025 Oportun Financial Corporation (OPRT) is expected to report $0.2 for Q3 2025 trivago N.V. (TRVG) is expected to report $0.07 for Q3 2025 Alle...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatmen...

– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a rare genetic disease primarily caused by variants in the OPA1 gene tha...

2025-10-16 11:17:03 ET More on the markets: Chair Powell's New Revelations On Monetary Policy Small Caps Don't Make All-Time Highs On The Cusp Of A Downturn 5 Trend Indicators For Deciding If The Bull Market Is Breaking Down U.S. stocks add to gains as more c...

2025-10-15 09:35:10 ET Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) traded at a new 52-week high today and are currently trading at $35.22. So far today, approximately 219.12k shares have been exchanged, as compared to an average 30-day volume of 1.18M shares. Stoke Therapeutic...

2025-10-10 09:15:08 ET Needham analyst issues BUY recommendation for STOK on October 10, 2025 11:37AM ET. The previous analyst recommendation was Buy. STOK was trading at $29.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status...